FS-222 is a Monoclonal Antibody owned by F-star Therapeutics, and is involved in 1 clinical trial, which is ongoing.

FS-222 acts by targeting cells expressing CD137 and PD-L1. PD L1 is an immune checkpoint generally overexpressed on tumor cells, promoting tumor cell proliferation and angiogenesis. Bi-specific monoclonal antibody binds to the antigens on tumor cell surfaces and activates the T cells against the specific cells through the signaling domains. This directs the cytotoxic T-cells response to specific antigen expressing tumor cells result in the killing of the tumor cells.

The revenue for FS-222 is expected to reach a total of $2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the FS-222 NPV Report.

FS-222 was originated by F-star Biotechnology and is currently owned by F-star Therapeutics.

FS-222 Overview

FS-222 is under development for the treatment of solid tumor. The drug candidate is a mAb-square immuno-regulatory monoclonal antibody. The therapeutic candidate consists of Fcab region in place of normal Fc region. It is a Bi-specific monoclonal antibody act by targeting cells expressing CD137 and PD-L1. It is administered through intravenous route.

F-star Therapeutics Overview

F-star Therapeutics, formerly Spring Bank Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company. It discovers and develops novel class of therapeutics. The company develops nucleotide-based drugs and small molecule nucleic acid hybrids. Its development pipeline products include FS118, FS120, FS222, SB 11285, among other drug candidates. The company’s drug products are used in the rescuing CPI treatment failures, improving outcomes in CPI naive, PD-L1 low tumors, chemotherapy outcomes, CPI outcomes, addressing unmet needs. Its partners programs include multiple blood brain barrier, multiple immuno-oncology, STING inhibitor, multiple next generation bispecifics. Spring Bank is headquartered in Hopkinton, Massachusetts, the US.

The company reported revenues of (US Dollars) US$21.2 million for the fiscal year ended December 2021 (FY2021), an increase of 88.1% over FY2020. The operating loss of the company was US$30.7 million in FY2021, compared to an operating loss of US$22.4 million in FY2020. The net loss of the company was US$31.3 million in FY2021, compared to a net loss of US$25.6 million in FY2020.

Quick View – FS-222

Report Segments
  • Innovator
Drug Name
  • FS-222
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.